Rosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, Lamorna Brown-Swigart, Christina Yau, Nicholas O'Grady, Amrita Basu, Ruixiao Lu, Michael J Campbell, Mark J Magbanua, Jean-Philippe Coppé, Smita M Asare, Laura Sit, Jeffrey B Matthews, Jane Perlmutter, Nola Hylton, Minetta C Liu, W Fraser Symmans, Hope S Rugo, Claudine Isaacs, Angela M DeMichele, Douglas Yee, Paula R Pohlmann, Gillian L Hirst, Laura J Esserman, Laura J van 't Veer, Emanuel F Petricoin
Molecular subtyping of breast cancer is based mostly on HR/HER2 and gene expression-based immune, DNA repair deficiency, and luminal signatures. We extend this description via functional protein pathway activation mapping using pre-treatment, quantitative expression data from 139 proteins/phosphoproteins from 736 patients across 8 treatment arms of the I-SPY 2 Trial (ClinicalTrials.gov: NCT01042379). We identify predictive fit-for-purpose, mechanism-of-action-based signatures and individual predictive protein biomarker candidates by evaluating associations with pathologic complete response...
December 5, 2023: Cell reports medicine